FIELD: chemistry.
SUBSTANCE: invention relates to a peptide represented by the formula (I) X1-Leu-X2-Leu-X3, where X1 is Glu or Asp, X2 is His, Lys or Arg, X3 is Asp or Glu, at that Glu, Asp, Leu, His, Lys and Arg, or its pharmaceutically acceptable salt and its compositions for treatment or prevention of cartilage damage and/or arthritis.
EFFECT: proposed peptide can affect the regeneration of cartilage tissue, inhibition of expression of the enzyme causing cartilage tissue matrix degradation, or inhibition of chondrosteosis.
7 cl, 2 tbl, 11 dwg, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS CONTAINING MESENCHYMAL STEM CELLS EXPRESSING GENE 6 INDUCED BY TUMOUR NECROSIS FACTOR | 2021 |
|
RU2822798C1 |
| THERAPEUTIC AGENT FOR CARTILAGE DISEASE | 2019 |
|
RU2813889C2 |
| FGF-18 IN TRANSPLANTATION AND TISSUE ENGINEERING PROCEDURES | 2015 |
|
RU2682159C2 |
| SCHEME FOR USING FGF-18 COMPOUND | 2015 |
|
RU2691946C2 |
| COMBINED COMPOSITION CONTAINING FGF-18 COMPOUND | 2016 |
|
RU2745453C2 |
| METHOD FOR PREVENTING AND TREATING ARTHROPATHIES AND METHODS FOR USING SAME | 2013 |
|
RU2521973C1 |
| HYALURONIC ACID BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION AND APPLICATION METHODS | 2012 |
|
RU2617844C2 |
| COMPOSITION FOR PREVENTION, RELIEF, OR TREATMENT OF DISEASES OR SYMPTOMS RELATED TO CARTILAGES, INCLUDING HAPLN1 | 2019 |
|
RU2788162C2 |
| PHARMACEUTICAL COMPOSITION, AGENT (VERSIONS) AND METHOD OF PREVENTING AND TREATING ARTHRITIS, OSTEOARTHROSIS AND VERTEBRAL OSTEOCHONDROSIS (VERSIONS) | 2012 |
|
RU2496511C1 |
| IMPLANT CONTAINING FGF-18 | 2015 |
|
RU2700414C2 |
